BRIEF-CMS Statement On FDA Accelerated Approval Of Lecanemab

Reuters · 01/06/2023 21:03
BRIEF-CMS Statement On FDA Accelerated Approval Of Lecanemab

Jan 6 (Reuters) -

  • CMS STATEMENT ON FDA ACCELERATED APPROVAL OF LECANEMAB

  • CMS - AT CMS, WILL CONTINUE TO EXPEDITIOUSLY REVIEW THE DATA ON PRODUCTS DESIGNED TO TREAT ALZHEIMER’S DISEASE AS THEY BECOME AVAILABLE

  • CMS - MAY RECONSIDER ITS CURRENT COVERAGE OF LECANEMAB BASED ON FDA REVIEW

  • CMS - IF LECANEMAB SUBSEQUENTLY RECEIVES TRADITIONAL FDA APPROVAL, CMS WOULD PROVIDE BROADER COVERAGE USING THE FRAMEWORK ANNOUNCED LAST YEAR


((Reuters.Briefs@thomsonreuters.com;;))